Vinay Prasad, a top regulator at the FDA, did not detail the data in the internal memo that led to the conclusion Pfizer and BioNTech developed the COVID-19 vaccine Comirnaty. Shares of Moderna and ...

Moderna shares on Friday were driven by multiple catalysts, including a Nasdaq-100 entry, a New York Times report on a ...

Using its mRNA platform, the company designed a COVID-19 vaccine candidate in just 42 days, leading to the rapid development and global deployment of Spikevax. This period catapulted Moderna from an R ...

Shares of Moderna and BioNTech fell on Monday, likely in response to a FDA official’s memo outlining a link between COVID-19 mRNA vaccines and myocarditis deaths in 10 children. Concern about that ...